会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明专利
    • Medicinal agent
    • 医药代理
    • JP2006131623A
    • 2006-05-25
    • JP2005292596
    • 2005-10-05
    • Genichiro Soma源一郎 杣
    • TAKIGUCHI KUNIOINAGAWA HIROYUKIKAWACHI CHIENISHIZAWA TAKASHISOMA GENICHIRO
    • A61K35/74A61P1/00A61P1/04A61P3/06A61P3/10A61P17/00A61P17/04A61P21/00A61P25/04A61P29/00A61P35/00A61P37/02C12N15/09
    • PROBLEM TO BE SOLVED: To provide a safe antiallergic therapeutic agent containing Posterisan and Eksalb and being a medicine or a medicinal agent using killed organism of gram-negative bacterium or gram-positive bacterium alone or in mixed state, because it is thought that new treating method for autoimmune diseases can be provided when macrophage activation is safely induced and IL-12 or the like can be produced, though an autoimmune disease such as atopic dermatitis, asthma or cancer is intractable and a therapeutic medicine effective for these diseases scarcely exists, while posterisan is a therapeutic medicine for hemorrhoids in which infection-protecting action and wound healing action are clinically recognized and generally used and active ingredient of the agent is killed organism liquid of Escherichia coli and it is suggested that the active ingredient safely induces macrophage activation, though the treating mechanism is not clear.
      SOLUTION: The agent having effect on atopic dermatitis model mouse is obtained by percutaneously using the suspension of Escherichia coli contained in posterisan.
      COPYRIGHT: (C)2006,JPO&NCIPI
    • 要解决的问题:为了提供含有Posterisan和Eksalb的安全的抗过敏治疗剂,并且是单独或混合使用革兰氏阴性细菌或革兰氏阳性菌的杀死生物体的药物或药剂,因为认为 当安全诱导巨噬细胞活化时可以提供自身免疫性疾病的新的治疗方法,尽管自身免疫性疾病如特应性皮炎,哮喘或癌症是难治性的,并且对这些疾病有效的治疗药物几乎不能产生IL-12等 存在,而后嗣是痔疮的治疗药物,其中感染保护作用和伤口愈合作用在临床上被认可和普遍使用,该药剂的活性成分是大肠杆菌的杀死生物体液体,并且建议活性成分安全地诱导巨噬细胞 激活,虽然治疗机制不明确。 解决方案:通过经皮使用包含在前列腺素中的大肠杆菌的悬浮液获得对特应性皮炎模型小鼠具有作用的药剂。 版权所有(C)2006,JPO&NCIPI